Talon Therapeutics Receives Special Protocol Assessment Agreement from the Food and Drug Administration for Its Phase 3 Confirmatory Study of Marqibo(R) in Newly Diagnosed Acute Lymphoblastic Leukemia
August 29, 2011 09:00 ET
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., Aug. 29, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), announced today the company has reached agreement with the U. S. Food and Drug Administration (FDA)...
Talon Therapeutics, Inc. Reports Second Quarter 2011 Financial Results
August 15, 2011 09:00 ET
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., Aug. 15, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and six months ended June 30, 2011.
"Submitting our new...
Talon Therapeutics to Host a Conference Call to Report Second Quarter 2011 Financial Results and Business Update on August 15, 2011
August 09, 2011 09:00 ET
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Monday, August 15, 2011 at 8:30AM PT, to include a discussion of results and...
Talon Therapeutics Announces First Patient Enrolled in National Cancer Institute Phase 1 Trial of Marqibo(R) in Children and Adolescents
July 20, 2011 09:00 ET
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., July 20, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced the enrollment of the first patient in a Phase 1 trial to evaluate the safety, activity and...
Talon Therapeutics Submits New Drug Application for Marqibo(R)
July 18, 2011 09:00 ET
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., July 18, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced its New Drug Application (NDA) for Marqibo (vincristine sulfate liposomes injection) was...
Talon Therapeutics Provides NDA Submission Timeline Update for Marqibo(R)
June 30, 2011 09:00 ET
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., June 30, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today provided an update of the status of its planned NDA submission for Marqibo ((vincristine sulfate...
Talon Therapeutics Presents Marqibo(R) Hematopoietic Stem Cell Transplantation (HSCT) "Bridging" Data at American Society of Clinical Oncology 2011 Annual Meeting
June 06, 2011 09:00 ET
|
Talon Therapeutics, Inc.
Marqibo enabled bridging to HSCT in 12 of 65 (18.5%) patients
There were 5 long-term survivors (greater than one year survival)
SAN MATEO, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- Talon...
Talon Therapeutics, Inc. Reports First Quarter 2011 Financial Results
May 13, 2011 09:00 ET
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., May 13, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON), today reported financial results for the first quarter ended March 31, 2011.
"Our primary focus for the...
Talon Therapeutics to Commence a Phase 3 Study of Marqibo(R) in Adult Patients With Newly Diagnosed Non-Hodgkin's Lymphoma (NHL)
May 10, 2011 09:00 ET
|
Talon Therapeutics, Inc.
Conducted by the prestigious German High-Grade NHL Study Group
R-CHMP (M=Marqibo) versus R-CHOP (O=standard vincristine)
Enrollment anticipated in third quarter 2011
SAN MATEO, Calif.,...
Talon Therapeutics to Host a Conference Call to Report First Quarter 2011 Financial Results and Business Update on May 13, 2011
May 09, 2011 09:00 ET
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., May 9, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Friday, May 13, 2011 at 8AM PT, to include a discussion of results and...